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ABSTRACT  
 Lactobacillus species are widely accepted as beneficial bacteria of the 
human microbiota1-8. Lactobacilli spp. are well documented to inhibit pathogens 
by production and secretion of hydrogen peroxide (H2O2), organic acids, and/or 
proteinaceous bacteriocins into their environment. Most research attributes 
bactericidal activity of cell free supernatant (CFS) to H2O2 and/or lactic acid. 
Here, I demonstrate that CFS from a clinical isolate of Lactobacillus crispatus 
contains a molecule(s) that inhibits uropathogenic Escherichia coli (UPEC) 
colony formation independently of H2O2 and organic acids. Physiologic 
concentrations of H2O2 and organic acids produced by L. crispatus do not inhibit 
UPEC colony formation. Incubation of UPEC with L. crispatus CFS has a 
bactericidal effect on UPEC that begins at about 4 hours and results in 
undetectable CFUs by 16 hours, apparently the result of severe plasmolysis. 
Bactericidal activity of this CFS is effective against some Gram-negative and 
Gram-positive species including multidrug resistant (MDR) E. coli. The broad-
spectrum activity shows CFS may have applicability as future therapeutic for 
treatment of various bacterial infections including MDR infections. 
The active molecule(s) present in CFS is stable over a wide temperature 
range and can be stored for at least 3 months while retaining full bactericidal 
activity. The active molecule(s) is sensitive to dilution and increased salt 
	 xvii	
concentrations. The active molecule(s) from CFS can be isolated via organic 
extraction. Based on the extraction profile, the molecule is predicted to be a 
dipolar organic molecule(s). The majority of proteins and tri-peptides are 
removed during organic extraction yet extracts retain full bactericidal activity. I 
conclude that L. crispatus produces a very stable potentially novel dipolar, 
organic molecule with broad-spectrum activity that is concentration-dependent 
and salt-sensitive, and which results in plasmolytic activity against its target. 
Isolation and identification of this molecule(s) could lead to application as a 
decontaminant or therapeutic. 	
		 	1	
CHAPTER I 
INTRODUCTION 
Previous Wolfe Laboratory Research 
Lactobacillus species are widely accepted as beneficial bacteria present in 
the gastrointestinal or vaginal tracts1-4, and recently within the lower urinary 
tract5-8. Using a novel culture technique, the Enhanced Quantitative Urine Culture 
(EQUC), members of the Wolfe laboratory have cultured organisms from the 
bladders of women with and without urinary bladder symptoms5-8. Lactobacillus 
crispatus was the most commonly cultured species from healthy controls without 
lower urinary tract symptoms9. Intriguingly, Lactobacillus crispatus and 
Escherichia coli rarely co-occurred9. This finding led Travis Price, a former MS 
student in the Wolfe laboratory, to investigate interactions between commonly 
cultured Lactobacillus species and Escherichia coli, which is implicated in 
numerous disorders of the urinary and reproductive tracts.  
Travis Price and Katherine Diebel, another former MS student in the Wolfe 
laboratory, have documented inhibition of uropathogenic Escherichia coli (UPEC) 
by a clinical isolate of Lactobacillus crispatus, Lc409-10. By first analyzing EQUC 
co-culture frequencies, Price noticed a low co-culture rate between L. crispatus 
and E. coli from samples obtained from the urinary bladder. Thus, he tested 
possible interactions between these species by performing a Spotted Lawn 
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assay. Price reported that Lc40 cells, but not cell free supernatant (CFS), 
inhibited the growth of uropathogenic and clinically obtained E. coli strains9 on 
agar plates. No zone of inhibition developed around the Lc40 cell spots, 
suggesting that inhibition by L. crispatus is contact-dependent. However, Price 
also determined that Lc40 CFS could inhibit the growth of UPEC in liquid culture 
and had considerably more activity against UPEC than did other species of 
Lactobacillus9. This finding would suggest L. crispatus has multiple mechanisms 
for the inhibition of other bacteria or the molecule(s) responsible for inhibition is 
not diffusible across/through agar plates. Because lactic acid and H2O2 are 
diffusible, this observation would suggest that these molecules are not 
responsible for Lc40’s ability to inhibit UPEC growth on agar plates. His results 
using L. gasseri differed from L. crispatus. L. gasseri cell spots on E. coli lawns 
did not show a zone of inhibition surrounding the spotted cells. Similar to L. 
crispatus, L. gasseri CFS was ineffective under plated conditions In contrast to L. 
crispatus, L. gasseri CFS partially inhibited UPEC in liquid cultures, but its did not 
effect was substantially less complete. 
Katherine Diebel repeated the work of previous researchers, by heating 
CFS or treating CFS with catalase10. In contrast to the former reports2,11, there 
was no increase of viable E. coli CFUs incubated in treated CFS when compared 
to untreated CFS10, suggesting that treatment of CFS does not decrease its 
efficacy. Diebel also validated  that the bactericidal activity of CFS was pH 
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dependent against UPEC12 by showing CFS buffered above pH 4.78 lost its 
inhibitory effect10.  
Together, the research of Price and Diebel has warranted further 
investigation into the inhibitory molecules of CFS as well as the mechanism of 
action against target cells. If a secreted molecule(s) is responsible for inhibition 
then it may have potential application as a future therapeutic. 
Common Lactobacilli Isolated from the Urinary Bladder 
The most commonly cultured Lactobacillus species from urinary bladder 
samples of women were L. crispatus, L. gasseri, L. iners, and L. jensenii13. This 
finding is consistent with research studying the vaginal microbiome14, where the 
four most commonly occurring Lactobacilli are the same as the four species of 
the urinary bladder. Three of these Lactobacillus spp. are associated with a 
healthy flora of the vaginal microbiota14-17. Research on the vaginal microbiota 
shows that an absence or decrease in Lactobacilli is associated with various 
disease states14-17. Research into the urinary microbiota is consistent with 
findings of the vaginal niche14,18.  
L. crispatus is commonly used as a probiotic and is widely accepted as a 
beneficial bacterium15-17,19-20. L. crispatus has been shown to have antimicrobial 
activity against many pathogenic bacterial species, including E. coli, Gardnerella 
vaginalis, and Chlamydia trachomatis1,19,21. It also may have the ability to 
regulate the vaginal microbiota by maintaining a Lactobacillus dominant flora 
rather than converting to a non-Lactobacillus dominant flora22. L. crispatus 
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maintains a Lactobacillus dominant microbiota better than L. gasseri or L. iners 
predominant women. Beyond the urogenital environment, L. crispatus is often 
used in the production and processing of dairy and fermented food products23. 
Use in the food industry is due to its anti-spoilage and anti-pathogenic properties. 
There have not been any documented detrimental aspects of L. crispatus 
colonization in various anatomical niches including both the urogenital and 
gastrointestinal tracts. 
L. gasseri is another commonly used organism in probiotics15-17,19-20. 
When used as a probiotic, it is speculated to assist in weight reduction in 
individuals who are overweight or obese24. L. gasseri has also been proposed to 
prevent periodontal disease and assist in immune system regulation when 
present in the gastrointestinal tract25. It has shown to be effective against 
pathogens such as E. faecalis, H. pylori, and L. monocytogenes23,26. It does not 
appear to have any negative effects on human health. 
 L. jensenii has been genetically modified to express human cell surface 
proteins (e.g. CD4) or to secrete antiviral drugs27-28 (e.g. cyanovirin-N). Both 
altered isolates were shown to reduce HIV infectivity. L. jensenii also inhibits 
Neisseria gonorrhoeae29. Similar to L. crispatus, L. jensenii is used during milk 
processing and fermentation processes due to antioxidant properties30. In 
contrast to both L. crispatus and L. gasseri, L. jensenii has been reported to 
cause disseminated infective endocarditis31. However, L. jensenii-induced 
endocarditis is rare. 
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 Although it is one of the most commonly cultured Lactobacilli, L. iners 
has not been shown to have any inhibitory or protective potential16,22,32. Women 
predominanted by L. iners are more susceptible to bacterial vaginosis than 
woman colonized by other Lactobacillus spp16. Analysis of the L. iners proteome, 
may suggest that specific proteins produced are possibly associated with vaginal 
dybiosis32. 
In general, the female urogenital tract is predominantly colonized by only 
one species of Lactobacillus. Both L. crispatus and L. gasseri have the most 
documented benefits to human health without documentation of detriment. Based 
on research performed by Travis Price, clinical isolates of L. crispatus have 
greater inhibitory activity against pathogens than L. gasseri. L. crispatus is also 
the most widely recognized beneficial Lactobacillus species among published 
research.   
Hydrogen Peroxide and Organic Acids 
Lactobacillus spp. are well documented to produce hydrogen peroxide 
(H2O2) and organic acids. Some species are also recognized to produce 
antimicrobial bacteriocins. H2O2 acts by inducing oxidative stress on target cells 
leading to the damage of cellular components including proteins, lipids, and 
nucleic acids33. Oxidative damage to nucleic acids results in irreversible 
alterations to the bacterial genome that ultimately results in death. Organic acids 
can act by permanently damaging target cell membranes or by permeabilizing 
the membrane, allowing antimicrobial molecules to enter target cells34. 
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Bacteriocins are sorted into multiple groups, which act against their target using 
different mechanisms. 
Both H2O2 and organic acids are secreted by Lactobacilli into their 
surrounding environment. Studies focusing on products secreted by Lactobacilli 
have used CFS derived from spent culture media to evaluate the antimicrobial 
effects of these secreted molecules. While many studies state that some 
Lactobacilli produce bacteriocins35-40, most of those studies attribute the 
bactericidal effects to lactic acid and/or H2O22,11,41-42. However, treatment of CFS 
with catalase or high temperatures to degrade H2O2 results in only moderate 
decreases in CFS efficacy against uropathogenic E. coli (UPEC), and not 
complete inhibition11,41-42. Additionally, it has been demonstrated that de Man, 
Rogosa, and Sharpe (MRS) broth, the standard culture medium for Lactobacilli, 
facilitates the rapid decomposition of H2O243. Rodrigeuz et al. supplemented 
MRS broth with 1-100mM H2O2 and measured OD405 over time. H2O2 
concentrations were determined to decrease over time by 90% of the originally 
supplemented concentration within a 24-hour period. In contrast, distilled water 
or phosphate-buffered saline supplemented H2O2 retained initially added H2O2 
concentrations when measured 24 hours after addition of H2O2. Based on these 
findings, it would seem unlikely that H2O2 is responsible for the bactericidal 
effects observed in untreated CFS. 
The previously cited studies2,11 did not determine the physiologic levels of 
lactic acid or H2O2 produced by the Lactobacillus species. These studies also did 
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not test physiologic concentrations of H2O2 or lactic acid, either individually or 
combined, against pathogens of interest. Instead, they tested arbitrary ranges of 
concentrations for each molecule to determine the minimum inhibitory 
concentration. The concentration of lactic acid produced by Lactobacillus spp. 
has been measured as ~62mM11. This concentration has been shown to only 
minimally inhibit pathogen colony formation11. Acetic acid concentrations have 
been measured in liquid cultures of L. sanfrancisco CB1 CFS as 13.8mM44, but 
the concentration produced by other Lactobacillus spp. has not been cited. H2O2 
production by various Lactobacilli has been measured with values ranging from 
0.03 to 2.6mM45. Inhibitory concentrations of H2O2 necessary to achieve 
inhibition required 2.5mM or greater, depending on the target pathogen11. 
Additionally, the physiologically produced concentrations of H2O2 would degrade 
in MRS broth, according to findings of Rodriguez et al43. 
When utilizing Dulbecco’s Modified Eagle Medium (DMEM) to neutralize 
the effects of lactic acid, CFS bactericidal activity was decreased, but still 
maintained some activity against some pathogens2,11. Unfortunately, the pH of 
the media supplemented with DMEM was not documented. Antimicrobial activity 
of some Lactobacilli CFS has been shown to be pH dependent and therefore pH 
cannot be negated as a factor in pathogen viability10,12. These investigators 
attributed inhibition solely to lactic acid and/or H2O2 and not the presence of other 
organic acids that may have been produced by Lactobacilli species. Research 
has shown that lactic acid and H2O2 can inhibit UPEC11,41-42; but, to achieve 
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these results, greater concentrations than are physiologically relevant must be 
used. This suggests that a molecule(s) other than lactic acid or H2O2 may be 
responsible for the remainder of UPEC inhibition. 
Antimicrobial Peptides and Bacteriocins 
Many pathogens have developed antibiotic resistance with associated 
increases in morbidity and mortality46. The increased rate of antibiotic resistance 
exceeds the development and identification of new antibiotic that may be 
effective against resistant strains. Consequently, only a limited cache of 
antibiotics exists to combat bacterial infections. Various bacterial species have 
been identified to produce molecules with bactericidal activity that may have 
application as new antibiotic treatments. For instance, recently researchers have 
identified lugdunin, a bacteriocidal molecule produced by Staphylococcus 
lugdunensis with efficacy against the colonization of methicillin-resistant 
Staphylococcus aureus, Glycopeptide intermediate-resistant S. aureus, 
vancomycin-resistant Enterococcus, and other infectious bacteria47. L. crispatus 
CFS also may contain many excreted, secreted or sloughed factors, which would 
include possible antimicrobial peptides and/or bacteriocins. If Lactobacillus 
crispatus CFS contains a molecule that is effective at inhibiting a broad spectrum 
of pathogens, then the molecule may be effective against antibiotic resistant 
strains with downstream application as an antimicrobial agent.  
 Antimicrobial peptides (AMPs) are small molecular weight peptides with 
broad spectrum activity48-51. Various AMPs have been identified and determined 
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to be produced by most organisms ranging from bacteria to mammals. AMPs 
tend to be amphipathic molecules and this characteristic allows for selective 
targeting of lipopolysaccharide membranes resulting in pore formation and loss 
of cellular membrane integrity. Researchers have also found correlations 
between AMPs and the mammalian immune response50-51. 
 Four major classes of AMPs have been identified. AMPs are classified 
based on their target organism48. The bactericidal activity of all AMPs involves 
the compromised integrity of cellular envelopes or membranes. Antiviral peptides 
act against viruses by integrating into the viral envelope52-53. Antibacterial 
peptides target bacterial membranes and act by compromising the bacterial lipid 
bilayer membrane54-55. Antifungal peptides can act by targeting either fungal 
membranes or internal cellular components56-57. Antiparasitic peptides form 
pores in the membranes of parasites58-59.  
Some bacterial species produce bacteriocins, which are proteinaceous 
molecules that have antimicrobial activity against closely related species35-36,39. 
Many bacteriocins have also been determined to be effectively bactericidal in 
nano- and picomolar concentrations. Beyond antimicrobial activity, some 
bacteriocins have been evaluated for their potential application as therapeutics 
including anticancer agents60. Bacteriocins are synthesized by ribosomes and 
are often encoded by plasmids, instead of the core genome of the producing 
bacterium38. Bacteriocins are classified based on numerous criteria, including but 
not limited to: method of production, mechanism of action, molecular weight, and 
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chemical properties37. Classification of bacteriocins differs between Gram-
negative and Gram-positive bacteria. Bacteriocins produced by Gram-negative 
species are generally classified based solely on size. Bacteriocins produced by 
Gram-positive species are classified based on the previously stated criteria and 
are grouped into Classes I-IV with some classes further separated into 
subclasses35,37-38. As L. crispatus is a Gram-positive bacterium, I will focus solely 
on Gram-positive bacteriocin classifications. 
 Class I bacteriocins are comprised of the lantibiotics that include the 
amino acid lanthionine and its derivatives. They are small (<5 KDa) in size and 
insensitive to protease degradation40. They are synthesized by Gram-positive 
bacteria and post-translationally modified to form intramolecular ring structures40. 
Intramolecular rings are formed through thioether bonds of internal cystine 
residues of lanthionine amino acids40. Two types of lantibiotics exist40. Type A 
lantibiotics are elongated, flexible, amphipathic peptides that act by forming 
pores in the cytoplasmic membrane of Gram-positive bacteria. By contrast, Type 
B lantiobiotics have a rigid, globular form and inhibit peptidoglycan synthesis of 
Gram-positive bacertia. 
 The Class II bacteriocins are heat-stable, allowing them to retain structure 
and function at elevated temperatures ranging from 100°C-121°C37-39. They do 
not contain lanthionine amino acids or its derivatives, have molecular weights 
<10 KDa, and tend to be amphipathic molecules with net positives charges. 
Class II bacteriocins are sub-categorized into subclasses based on genetic 
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consensus sequences. Class IIa are considered to be listeria-active 
bacteriocins but have overall broad range activity. However, the broad range of 
activity is not well defined. If this subclass acts on organisms that are 
phylogenetically distant from the producing organism than these molecules do 
not fit the definition of a bacteriocin. These act against their target by 
permeabilizing cellular membranes61. Class IIb bacteriocins require two peptides 
for activity and compromise bacterial membranes by pore formation62. Subclass 
IIc bacteriocins are cyclic, thiol activated peptides that require cysteine residues 
for activity63. Two additional, but minor, subclasses are subclass IId and IIe.  
 Class III bacteriocins are larger in size (>30 KDa) than Class I or II64. This 
class contains proteins with enzymatic function. Subclass IIIa degrade cellular 
membranes leading to cell lysis. Subclass IIIb act by altering cell membrane 
potential leading to ATP efflux from cells, and ultimately cell death. Class III 
bacteriocins are heat-labile and denature with increased temperature. 
 Class IV bacteriocins do not have definitive classification criteria. 
Molecules placed into Class IV do not meet the criteria of the previously 
mentioned classes. These are considered complex bacteriocins and are 
generally conjugated with carbohydrates or lipids38,65-66. Other characteristics of 
molecules in this class vary and there is not a currently identified consensus 
sequence allowing for grouping into Class IV.	
Lactobacillus CFS has been tested on a wide range of bacteria with 
varying phylogenetic relatedness2-4,11-12,34,44-45,47,67-69. However, Escherichia and 
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Salmonella, both phylogenetically unrelated to Lactobacillus, are susceptible to 
Lactobacillus CFS11-12,67. Because bacteriocins are defined as only being 
bactericidally active against closely related organisms, the activity of 
Lactobacillus CFS does not fit into the classical definition of a bacteriocin. This 
suggests that the active molecule against these genera is not likely to be a 
bacteriocin.  
Proteins and polysaccharides tend to be very immunogenic and therefore 
one would expect increased cytokine production if the inhibitory molecule were 
one of these two compounds. Nucleic acids and lipids tend to not induce an 
immune response. Researchers have incubated vaginal epithelial cells with CFS 
from L. crispatus reference strain CTV05 and documented that they do not 
exhibit an immune response, as measured by pro-inflammatory cytokine levels1. 
Therefore, based on previous observations, it would be suggested that the 
inhibitory molecule present in Lc40 CFS is unlikely to be a protein or 
polysaccharide.  
Lc40 CFS activity has been shown to be insensitive to heat and has broad 
spectrum activity against phylogenetically unrelated genera. Due to these results 
it would seem unlikely that the bactericidally active molecule(s) in Lc40 CFS is a 
bacteriocin, with the exception that it may be a Class IIa bacteriocin. I 
hypothesize that the bactericidal molecule(s) of Lc40 CFS is likely an 
antibacterial AMP. 
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Inhibition and Mechanism of Action 
A mechanism of action for the inhibition of bacteria by Lactobacillus CFS 
has not been proposed. Spotted lawn assays were performed using Lc40 cells or 
filter sterilized CFS. Under plated conditions Lc40 cells, but not CFS, had an 
inhibitory effect against UPEC. Yet, liquid cultures containing CFS do have 
inhibitory effects. This may suggest Lc40 has more than one mechanism of 
inhibition or the molecule produced is either hydrophobic or has a low solubility.  
Based upon data presented by others it seems unlikely bacterial inhibition 
by L. crispatus is due to classically defined bacteriocins, lactic acid, or H2O2. The 
necessity to use greater than physiologically produced concentrations of lactic 
acid and H2O2 to achieve inhibitory effects shows that inhibition cannot be 
attributed to either of these molecules1-3,11,44-45,68,70. Due to the heat stability of 
CFS and phylogenetic distance between L. crispatus and E. coli, the inhibitory 
effect is also not likely to be due to a bacteriocin, peptide, or protein. If the active 
molecule(s) is a bacteriocin then it is either a Class II bacteriocin or a previously 
unidentified class. It is being suggested that L. crispatus produces a potentially 
novel molecule, or class of bacteriocin not previously identified, which I intend to 
identify.  
If L. crispatus produces a novel molecule that could be used as a 
decontaminant or therapeutic, then we must understand the mechanism of 
action. Knowledge of the mechanism would help evaluate the spectrum of activity 
against pathogenic and non-pathogenic bacterial strains. If this molecule acts 
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against pathogens with little or no damage to commensal bacteria of the host, 
then this could be a good therapeutic. However, similar to many antibiotic 
treatments, if this molecule eliminates commensal/symbiotic bacteria of the host, 
then it may have negative downstream effects on host health. As a mechanism of 
action for the inhibition of pathogens has not been investigated, the morphology 
and integrity of target cells has not been characterized. This should be a first step 
in order to understand the mechanism by which inhibition of colony formation 
occurs.  
Through my research, I intend to identify the bactericidal molecule(s) 
present in CFS and determine a mechanism of action.	
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CHAPTER II 
MATERIALS & METHODS 
Bacterial Strains and Culture Conditions 
Culture Conditions 
Escherichia coli E. coli (CFT073, NU14, or UMB901) was plated on 
Blood Agar plates (BAP) from a frozen stock. Plates were then incubated at 37°C 
aerobically for 24 hours. After 24 hours, a single colony was obtained from BAP 
and used to inoculate 6 mL of Tryptic Soy Broth (TSB). The culture was then 
incubated at 37°C aerobically on a shaker for 24 hours. 
Enterococcus faecalis E. faecalis clinical isolate UMB891 was plated on 
BAP from a frozen stock. Plates were incubated in 5% CO2 at 37°C for 48 hours. 
After 48 hours, multiple colonies were transferred using a sterile cotton swab 
from BAP into 6 mL TSB supplemented with 5% FetalPlex™ animal serum 
complex (Gemini Bio-Products). The inoculum was incubated at 37°C in 5% CO2 
for 48 hours. 
Lactobacillus crispatus Clinical isolate Lc40 of L. crispatus was plated 
onto BAP from a frozen stock and incubated in 5% CO2 at 37°C for 48 hours. 
After 48 hours, multiple colonies were transferred from BAP into 6 mL de Man, 
Rogosa, and Sharpe (MRS) Broth71. The culture was then incubated statically in 
5% CO2 at 37°C for 48 hours. 
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Staphylococcus aureus S. aureus clinical isolate UMB910 was plated 
in BAP from a frozen stock and incubated aerobically at 37°C for 24 hours. After 
24 hours, a single colony was obtained to inoculate 6mL TSB. The inoculum was 
then incubated aerobically at 37°C statically. 
Sample Preparation 
E. coli, E. faecalis, and S. aureus 100 µL of overnight cultures (O/N) 
were added to 900 µL of TSB. The optical density (OD600) of these cultures was 
then obtained using the Eppendorf BioPhotometer® D30 with TSB as a blank. All 
samples were then standardized to a final an OD600 of 1.0. 
L. crispatus 48-hour liquid cultures were centrifuged at 3500 rpm for 10 
minutes to pellet bacterial cells. The supernatant liquid was then filter sterilized 
using a 0.22µm filter to remove bacterial cells and obtain a cell free supernatant 
(CFS). To determine CFS activity over Lc40 growth OD600 was measured every 
six hours. 48-hour liquid cultures were standardized to an OD600 of 0.05 in 6 mL 
of MRS. Measurements were obtained using MRS medium as a blank. Samples 
were measured by adding 100 µL of culture to 900 µL of MRS to measure a 1:10 
OD600.  
Inhibitory Molecule Concentrations 
Hydrogen Peroxide Concentration 
Hydrogen peroxide concentrations were determined by titration72. CFS 
was prepared as indicated in Methods Sample Preparation. Hydrogen Peroxide 
(H2O2) concentration in CFS was determined by titration of potassium 
		
17	
permanganate (KMNO4) into CFS diluted in water and sulfuric acid (H2SO4)72. 
KMNO4 is a purple solution, whereas the CFS solution is clear.  As KMNO4 is 
titrated into the CFS solution, it will gradually turn from a clear to pink solution, 
but will revert rapidly back to clear. Once an equivalence point is reached, the 
solution will remain pink. The volume of KMNO4 needed to reach equivalence is 
then used to determine the concentration of H2O2 in CFS. Sterile water and a 
commercial 3% H2O2 solution were used as negative and positive controls, 
respectively. 
Organic Acid Concentration 
Acetic and lactic acid concentrations in CFS were determined using 
commercially available kits from Boehringer Mannheim73,74. 
Protein Quantification 
The bicinchoninic acid assay (BCA) was followed per supplier 
instructions75 to quantify protein concentrations in MRS and CFS. The samples 
were read at 562 nm using Molecular Devices SpectraMAX 250 plate reader and 
SOFTmax Pro software. Bovine Serum Albumin was used as the standard. 
Quantification of Conditioned Medium Effect against E. coli 
UPEC Incubation with CFS, Conditioned-Medium, and MRS 
The volume of overnight UPEC cultures grown in TSB needed for an 
OD600 of 1.0 in a final volume of 200 µL was determined. The determined 
volume was added to 100 µL CFS, conditioned medium, or MRS. Cultures were 
then brought to a final volume of 200 µL by addition of TSB. The mixed samples 
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result in a final UPEC OD600 of 1.0 (~1.0x108 cells). Samples were prepared 
in 96 well plates. Wells were covered with Parafilm™ to prevent evaporation of 
samples. Plates were then incubated at 37°C aerobically on a shaker overnight. 
Serial Dilutions 
Serial dilutions were performed in 96 well plates with each well containing  
180 µL Phosphate Buffered Saline (PBS) or dH2O. 20 µL of sample were added 
to the first row using a multi-channel pipette. Samples were then mixed by 
pipetting samples ~30 times before transferring 20 µL to the next row. Pipette 
tips were changed between sample transfers. This row was mixed using the 
above method and 20 µL transferred to the next well. 1:10 serial dilutions were 
carried out by repeating this process through the 8th row of the 96 well plate 
(Figure 1).  
 
Figure 1. Serial dilutions performed in a 96-well plate 
 
Cell Quantification 
Samples from each well were plated onto Tryptic Soy Agar (TSA) plates. 
Plates were divided into 4 equal sections, one for each dilution factor of a sample 
20	μL	of	original	sample	
Transfer	20	μL	of	previous	dilution	to	subsequent	well	
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(Figure 2). 10 µL of each sample dilution were spotted onto the TSA plates in 
the section respective of their dilution. Triplicates of samples were spotted in the 
same quadrant. The spots were allowed to dry before plates were inverted and 
incubated at 37°C aerobically for 24 hours. After 24 hours colonies were counted 
and used to quantify average cells/mL by the following formula: !"##$!" = !"## !"#$% ! (10!"#$%"&' !"#$%&!!) 
Additional dilution factors are added because 10 µL of a 1:10 dilution is plated 
resulting in additional dilution factors. The mean and standard deviation of 
triplicates were then calculated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Plating of serial dilution spots from a 96-well plate. 
 
Survival Graphs 
Graphs were constructed using the mean of cell counts under each 
condition at the 24-hour time point. Red dotted lines on each graph represent the 
detection limit of colony-forming units following serial dilution. The first dilution 
10-1	
10-2	10-4	
10-3	
10-1	
10-2	10-4	
10-3	
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plated is a 1:10 dilution and 10µL of each dilution are plated. Therefore, the 
limit of detection was calculated as 103 cells.  
CFS Concentration and Dilution 
CFS Concentration 
CFS concentration was performed using the Savant Integrated SpeedVac 
System ISS110. 1 mL aliquots of CFS were placed into the SpeedVac, which 
uses heat and centrifugation to concentrate all non-liquid components within the 
CFS. Once the liquid was evaporated, then the components were re-suspended 
in 50 µL (20X) or 100 µL (10X) of H2O at pH 3.7 or 7.0. 
CFS Dilution 
CFS was diluted by adding either H2O pH 3.7 or PBS pH 3.7 to non-
concentrated CFS to obtain specific dilution factors, e.g. 90% CFS in a final 
volume of 500 µL = 450 µL CFS and 50 µL H2O/PBS. 
CFS Fractionation 
Fast Protein Liquid Chromatography 
An Amersham Biosciences FPLC was used to perform CFS fractionation 
by size. 200 µL of CFS was injected into and run through a Superose 6 10/300 
GL column in a Tris buffer pH 8.0 at 0.6 mL/min and collected in 1 mL fractions. 
Additional runs were performed using PBS pH 3.7 rather than Tris. The first run 
was performed at an elution rate of 0.6 mL/min collected in 1 mL fractions. The 
second was run at rate of 0.06 mL/min and collected in 300 uL and/or 1 mL 
fractions. 
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Liquid-Liquid Organic Extraction 
Liquid-liquid organic extraction was performed following a modified  
Method76. Solvents were added starting at a 1:1 ratio to 10X concentrated CFS 
samples or MRS. Samples were mixed by vortexing and then centrifuged to 
separate organic and aqueous layers. The two layers were then separated by 
pipet into sterile Eppendorf tubes. Sample liquids were then evaporated 
overnight by SpeedVac and re-suspended as previously mentioned.  
Immunofluorescent Stains 
Live/Dead Staining 
Cells incubated for 24 hours with Lc40 CFS were stained using the 
Invitrogen LIVE/DEAD BacLight Bacterial Viability Kit77. This kit uses SYTO-9 
and propidium iodide nucleic acid fluorophores. SYTO-9 readily enters cells with 
and without damaged cell membranes. Propidium iodide is a larger molecule and 
only enters cells with compromised membranes. Fluorophore properties are 
listed in TABLE 1. 
Fluorophore Color Molecular 
Weight 
Excitation Emission 
Syto978 Green 400 480nm 500nm 
Propidium 
Iodide79 
Red 668 490nm 635nm 
FM 4-6480 Red 608 515nm 640nm 
Hoescht 3334281 Blue 616 361nm 497nm 
TABLE 1. Fluorophore Properties. 
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Membrane and Nucleic Acid Stains 
Sample Preparation UPEC cultures were standardized to an OD600 of 
1.0 prior to being incubated in CFS or MRS. 200 µL of sample were obtained 
hourly and centrifuged at 13500 rpm for 1.5 minutes. Supernatants were 
removed by pipette and samples were washed with 100 µL dH2O. Samples were 
centrifuged again at 13500 rpm for 1.5 minutes. Supernatants were removed by 
pipette and samples were re-suspended in 100 µL H2O.  
Slide Preparation and Sample Staining 10 µL poly-L-Lysine was spotted 
on microscope slides and allowed to sit for 1 minute. Liquid was then suctioned 
off by vacuum pipette. Spots were washed 2x with H2O and dried. 10 µL of 
sample was applied to Lysine spotted regions and allowed to sit for 10 minutes. 
Excess sample was then suctioned off and the plates were dried. 0.05 µg 
Hoeshct nucleic acid dye was added to samples in a dark room and incubated for 
10 minutes. Excess dye was suctioned off and samples were washed once with 
H2O. 0.01 µg FM 4-64 membrane specific fluorophore was then added to 
samples, incubated for 30 seconds then excess dye removed and samples were 
washed once. Coverslips were added to samples. 
Imaging 
Samples were imaged using the Leica DMIRB microscope at 1000X and 
images were captured using MagnaFire 2.1C software. Images were obtained in 
the red, blue, and bright fields. Images were merged using ImageJ software to 
obtain final composite images. 
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Statistics 
One-way ANOVA and/or Mann-Whitney U tests were performed on raw 
data to determine statistical significance between variables. Statistical 
Significance will be denoted as follows: * = p<0.05, ** = p<0.01. 
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CHAPTER III 
DETERMINATION OF KNOWN OR PROSPECTIVE BACTERICIDAL 
MOLECULES PRESENT IN LACTOBACILLI CELL FREE SUPERNATANT 
Introduction & Rationale 
 Using a novel culture technique, the Enhanced Quantitative Urine 
Culture (EQUC), researchers have cultured organisms from the bladders of 
women with and without urinary bladder symptoms5-8. Based on the organisms 
cultured from these specimens, the co-culture frequency of various organisms 
was determined9. The most commonly cultured Lactobacillus species from these 
samples were L. crispatus, L. gasseri, L. iners, and L. jensenii. Intriguingly, of 
these species, L. crispatus had a significantly lower co-culture frequency with 
Escherichia coli and spotted lawn assays showed inhibition of uropathogenic E. 
coli (UPEC) by L. crispatus cells, but not by L. gasseri9. The inhibition of UPEC 
by L. crispatus, however, did not result in a zone of inhibition surrounding the L. 
crispatus cell spot and L. crispatus cell free supernatant (CFS) did not show 
inhibitory activity when spotted onto a UPEC lawn. In UPEC liquid cultures, 
however, L. crispatus CFS inhibited growth and colony formation when plated9. 
The ability of CFS to inhibit UPEC in liquid culture but not on agar plates 
suggests the production of a secreted molecule that is concentration dependent 
and/or not diffusible. 
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Lactobacilli are a Gram-positive genus commonly cultured from the 
gastrointestinal and urogenital tracts of women. Lactobacilli are widely 
recognized as beneficial by providing an additional barrier beyond the host 
defenses that inhibit pathogen colonization1-4. Most previous research attributes 
bactericidal activity of Lactobacilli to the production of hydrogen peroxide (H2O2) 
and organic acids, predominantly lactic acid1-3,11,44,46,68,70. Certain Lactobacillus 
spp. also have been recognized to produce bacteriocins responsible for 
pathogen inhibition2,4,35,82.  
The concentration of lactic acid produced by Lactobacillus spp. has been 
measured as ~62mM11. This concentration has been shown to only minimally 
inhibit pathogen colony formation11. Acetic acid concentrations have been 
measured in liquid cultures of L. sanfrancisco CB1 CFS as 13.8mM44, but the 
concentration produced by other Lactobacillus spp. has not been cited. H2O2 
production by various Lactobacilli has been measured with values ranging from 
0.03 to 2.6mM45. Inhibitory concentrations of H2O2 necessary to achieve 
inhibition required 2.5mM or greater, depending on the target pathogen11.  
Hydrogen Peroxide Concentration in CFS 
 If H2O2 were responsible for the bactericidal activity of CFS, then we 
would expect concentrations greater than the concentrations shown to inhibit 
pathogens11. Measurement of H2O2 in CFS had a mean value of 11.51 +/- 
0.000006 µM (TABLE 2), lower than concentrations measured45 by previous 
researchers, and at least 10-fold lower than concentrations documented to result 
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in pathogen inhibition11. This result would suggest H2O2 is unlikely to 
contribute to the bactericidal activity of CFS. 
Organic Acid Concentration in CFS 
 CFS was prepared as indicated in Methods Sample Preparation. Organic 
acid concentrations were determined using commercially available kits from 
Boehringer Mannheim73-74. In short, each kit utilizes enzymes that convert 
acetate or lactate to molecules that can be measured by UV-Vis Spectrometry.  
Optical density (OD600) measurements of converted molecules can then be 
used to determine concentrations of acetic and lactic acids present in CFS. 
 If acetic or lactic acids contribute to the bactericidal activity of CFS, as with 
H2O2, we would expect concentrations similar to or in excess of concentrations 
mentioned prior11. Acetic and lactic acid concentrations averaged 7.26 +/- 0.059 
mM and 9.52 +/- 0.011 mM, respectively (TABLE 2). The acetic acid 
concentration in CFS was considerably lower than the cited inhibitory 
concentrations44. The lactic acid concentration present in CFS also was much 
lower than concentrations documented to be necessary for pathogen inhibition11. 
As with H2O2, the concentration of organic acids produced by L. crispatus are 
unlikely to contribute to pathogen inhibition. 
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CFS Molecule Inhibitory Concentration 
Average 
Lactobacilli 
Concentration 
Lc40 Produced 
Concentration 
Hydrogen Peroxide 2.5 mM11 0.03 – 2.6 mM45 11.51 +/- 0.000006 µM 
Lactic Acid 70 mM11 62 mM11 9.52 +/- 0.011 mM 
Acetic Acid 8.33 mM44 13.8 mM44 7.26 +/- 0.059 mM 
Table 2. Concentrations of known inhibitory molecules in Lc40 CFS. 
Hydrogen peroxide concentrations were determined by titration. Organic acid 
concentrations were determined by UV-Vis spectrophotometry. H2O2 and organic 
acid concentrations in CFS were lower than concentrations determined to exhibit 
inhibitory activity against pathogens. 
 
H2O2 and Organic Acid Conditioned-Medium against UPEC 
 To determine each molecule’s contribution to CFS bactericidal activity, 12 
µM H2O2, 7.5 mM Acetic acid, and 8.5 mM Lactic acid were individually added to 
MRS medium (pH 3.7) and incubated with UPEC overnight. The molecules also 
were combined in MRS at the same final concentrations to determine their 
combined bactericidal activity. As a positive control, CFS was added to UPEC 
cultures as previously described and incubated overnight. CFUs were quantified 
at 0- and 24-hour time points to determine the killing activity of conditioned 
medium. MRS conditioned with H2O2 and/or organic acids at the measured 
concentrations did not inhibit colony formation by UPEC (Figure 3). Thus, we 
conclude that the bactericidal activity cannot be due to H2O2 and organic acids. 
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Figure 3. Contributions of physiologic concentrations of H2O2 and organic 
acids to bactericidal effects of L. crispatus CFS. 12µM H2O2, 8.5mM lactic 
acid, and 7.5mM acetic acid were added to MRS medium pH 3.7 at 
concentrations listed in Table 1. MRS supplemented with physiologically 
produced concentrations of H2O2 and organic acids did not result in bactericidal 
activity against UPEC. 
 
Temperature and Time Stability 
 It has been shown here that H2O2 and organic acids are not responsible 
for bactericidal effects of CFS. To begin investigating the type of molecule 
responsible for bactericidal activity, as well as test molecule stability, CFS was 
subjected to different storage temperatures and times. Proteins tend to denature 
with extreme decreases or increases in temperature69,83. Boiling or cooling CFS 
would, therefore, denature most proteins present within CFS and negate their 
bactericidal effect against UPEC. Finally, lactic acid and hydrogen peroxide 
degrade over time and at different temperatures. The half-life of lactic acid 
ranges from 8-21 days, while hydrogen peroxide spontaneously decomposes to 
O2 and H2O over time. The decomposition rate of H2O2 is increased with both 
light exposure and at higher temperatures84.   
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CFS was prepared as previously described. CFS samples were then 
subjected to 100°C, 25°C, or 4°C temperatures. 100°C samples were held at 
constant temperature for one hour then stored at 25°C. 4°C samples were stored 
at 4°C. Samples from each temperature condition were then stored for either one 
or fourteen days prior to UPEC incubation. 
When UPEC was incubated with temperature- or time-conditioned CFS, 
there was no change in bactericidal activity when compared to untreated CFS 
(Figure 4). These results suggest typical proteins do not contribute to the 
bactericidal activity of CFS. 
I have previously shown that bactericidal activity is preserved when CFS is 
stored at different temperatures for up to 2 weeks. I have not determined if CFS 
is stable when stored for longer than two weeks. Therefore, I stored CFS at room 
temperature (25°C) for three months and then tested its activity against UPEC. 
CFS retains full bactericidal activity against UPEC when stored at room 
temperature up to three months (Figure 5). 
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 Figure 4. CFS held up to 2 weeks at different temperatures retains its 
bactericidal activity against UPEC. CFS samples were subjected to 100°C, 
25°C, or 4°C temperatures and then stored for either one or fourteen days. 
100°C samples were held at constant temperature for one hour before being 
stored at 25°C for the specified times. 4°C samples were stored at 4°C for the 
specified times. Conditioned CFS retained full bactericidal activity when 
compared with unconditioned CFS. 
 
 
Figure 5. CFS Activity after storage at room temperature for three months. 
CFS retains full bactericidial activity against UPEC when stored up to three 
months at room temperature (25°C). 
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CHAPTER IV 
IDENTIFICATION OF THE INHIBITORY MOLECULE(S) IN CFS 
CONTRIBUTING TO BACTERICIDAL ACTIVITY 
Introduction & Rationale 
 To determine the type of molecule contributing to the bactericidal effects 
against UPEC, enzymatic treatment was considered. Most enzymes are only 
effective within narrow pH ranges and rarely under acidic conditions. The pH of 
CFS after filter sterilization is 3.710. At this pH, enzymatic treatment would be 
ineffective. Furthermore, CFS was previously determined to be ineffective at 
more neutral or basic pH10,82. In one study, bactericidal activity of CFS was 
regained after re-acidification of CFS82. Therefore, neutralization, enzymatic 
treatment, and re-acidification may be a viable approach to degrade specific 
classes of molecules and determine the class of the bactericidally active 
molecule(s) in CFS. 
Organic extraction is a common technique used to fractionate and/or 
purify organic compounds. In liquid-liquid extraction, solvents are added to a 
liquid sample and mixed. After centrifugation, the mixture resolves into two 
separate phases, an aqueous phase and an organic phase. The aqueous phase 
contains remnants of the original sample. Molecules from the original sample 
sharing properties with the chosen solvent will migrate into the organic phase. 
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Solvents are chosen based on their miscibility in water and/or other 
properties, such as polarity85. General properties of solvents include miscibility, 
organic versus inorganic, polar versus non-polar, and protic versus aprotic. 
Miscibility refers to the ability of a solvent to mix with water. Organic solvents 
contain carbon atoms whereas inorganic solvents do not. Polar solvents have a 
net charge. Dipolar solvents move electrons between atoms and therefore have 
a small moving charge throughout the molecule. Non-polar solvents have no net 
charge. Protic solvents have the capability to donate H+ ions, whereas aprotic 
solvents cannot. 
Solvent properties are not mutually exclusive and some solvents have 
many of the above properties. Polar protic solvents have a polar group on one 
end (e.g. –OH) and a non-polar group on the other. Dipolar aprotic solvents have 
a slight moving charge and cannot donate H+ ions to sample molecules. Non-
polar solvents tend to be hydrophobic and immiscible in water. Characteristics of 
select organic solvents are listed in TABLE 3. 
Solvent 
 
IUPAC 
Name 
Solvent 
Type 
Miscible 
with H2O 
Polar Polarity 
Index 
Protic 
or 
Aprotic 
1-Butanol n-Butanol Alcohol Immiscible Polar 0.586 Protic 
Acetone Acetone Ketone Miscible Dipolar 0.355 Aprotic 
Acetonitrile Acetonitrile Misc. Miscible Dipolar 0.460 Aprotic 
Benzene Benzene Hydrocarbon Immiscible No 0.111 aprotic 
Chloroform Chloroform Chlorinated 
Solvent 
Immiscible Slightly 0.259 Aprotic 
Ethyl 
Acetate 
Ethyl 
Acetate 
Ester Immiscible Dipolar 0.228 Aprotic 
Petroleum 
Ether 
n-Pentane Hydrocarbon Immiscible No 0.009 Aprotic 
Table 3. Solvent Properties. Properties of Solvents used in liquid-liquid organic 
extractions (see Figures 16 & 17)85. 
		
33	
 
 
Figure 6. Solvent Structures. Skeletal structural formulas of solvents used in 
liquid-liquid organic extractions86. 
 
Size Determination 
Fast Protein Liquid Chromatography (FPLC) 
I attempted FPLC to identify a fraction with bactericidal activity. This 
method would facilitate purification and size range determination of bactericidally 
active molecules. Three separate runs were performed with different eluents and 
elution rates. No active fractions were identified (Figures 7-9). 
Size Exclusion Spin Columns 
 
 I used low-binding centrifuge spin columns in an attempt to fractionate 
samples by size exclusion and determine an approximate size range of the active 
bactericidal molecule(s). 3-100kD columns were used. Size fractionation of CFS 
resulted in fractions without bactericidal activity (data not shown). Size 
determination at this time has been unsuccessful. 
1-Butanol	
Acetone	
Acetonitrile	
Ethyl	Acetate	
Chloroform	
Benzene	
Petroleum	Ether	
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Figure 7. FPLC of CFS Eluted in Tris pH 8.0. The sample was eluted at a rate 
of 0.6mL/min and collected in 1mL fractions. Fractions were incubated with 
UPEC for 24 hours. Fractions did not exhibit bactericidal activity. 
 
 
 
Figure 8. FPLC of CFS Eluted in PBS pH 3.7. The sample was eluted at a rate 
of 0.6mL/min and collected in 1mL fractions. Fractions were incubated with 
UPEC for 24 hours. Fractions did not exhibit bactericidal activity. 
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Figure 9. FPLC of CFS Eluted in PBS pH 3.7. The sample was eluted at a rate 
of 0.06mL/min and collected in 300µL fractions. Fractions were incubated with 
UPEC for 24 hours. Fractions did not exhibit bactericidal activity. 
 
CFS pH Neutralization and Acidification 
 To treat CFS with enzymes targeting specific types of molecules, CFS 
would need to be neutralized and re-acidified. CFS was neutralized to pH 7.0 
using 1N NaOH then acidified to pH 3.7 using 1N HCl. The volume of NaOH/HCl 
required resulted in less than a 10% dilution of CFS. However, neutralized and 
re-acidified CFS lost all activity against UPEC (data not shown). 
CFS Dilution and Concentration 
CFS Dilution 
I suspected that FPLC was unsuccessful due to dilution of the active 
molecule(s) in CFS. To determine if CFS bactericidal activity was concentration-
dependent, CFS was diluted in 10% increments in either dH2O or phosphate-
buffered saline (PBS) adjusted to pH 3.7. Each dilution was incubated with UPEC 
overnight and CFUs quantified at 0 and 24 hour time points.  
 When CFS was diluted by 75% (50% prior to adding UPEC culture), it lost 
all bactericidal activity against UPEC (Figure 10). FPLC would dilute CFS 
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substantially more than 75% and therefore this loss of activity would explain 
why no active fractions could be identified from FPLC experiments. Bactericidal 
activity appears to be salt-sensitive. Dilutions performed in PBS exhibited greater 
activity against UPEC than dilutions performed in dH2O (Figures 11 & 12). 
Together, these results show CFS bactericidal activity is salt-sensitive and 
concentration-dependent. 
 
Figure 10. CFS dilutions in H2O pH 3.7. CFS was diluted in 10% increments 
prior to being added to UPEC cultures. Dilution in H2O shows a logarithmic 
decrease in bactericidal activity against UPEC and CFS losses all activity at a 
50% concentration. 
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Figure 11. CFS dilutions in PBS pH 3.7. CFS was diluted in 10% increments 
prior to being added to UPEC cultures. CFS loses bactericidal activity when 
diluted 50%.  
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Figure 12. CFS diluted in H2O versus PBS. CFS diluted in PBS retains 
bactericidal activity at greater dilutions than when CFS is diluted in dH2O.  
 
CFS Concentration 
 To determine if loss of activity due to CFS dilution could be controlled, 
CFS was concentrated. CFS was aliquoted into Eppendorf tubes in 1 mL 
volumes. Samples were then lyophilized by SpeedVac overnight. Samples were 
re-suspended in 50-100 µL H2O pH 3.7 to obtain 10-20X concentrated CFS. 
Concentrated CFS was then incubated with UPEC (Figure 13). Concentrated 
CFS showed complete bactericidal activity against UPEC. Therefore, 
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experiments resulting in dilution could be used to determine characteristics 
and purify the bactericidal molecule(s) in CFS.  
 
Figure 13. Concentrated CFS activity against UPEC. CFS was concentrated 
20X by SpeedVac. Concentrated CFS retains full bactericidal activity against 
UPEC. 
 
CFS Activity on Agar Plates 
 
 Price and Diebel previously determined that CFS only showed bactericidal 
activity in liquid culture but not on agar plates9-10. CFS activity has also been 
determined to be pH-dependent with a loss of activity above pH 4.5 but in one 
study acidification of CFS restored activity. To determine if inactivity of CFS of 
plates was due to pH, I measured the pH. The pH of TSA plates is ~7.5 prior to 
addition of CFS while CFS pH is 3.7. After plating 100µL of CFS pH is measured 
as 3.7 but after CFS dries the plate pH increases to 7.0. pH was measured after 
the plate was incubated for 24 hours and pH remains at 7.0. These results may 
explain the lack of activity observed when CFS is spotted onto plates.  
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I attempted to regain CFS bactericidal activity on agar plates by 
performing lawn assays. UPEC overnight cultures were standardized to OD 1.0 
and used to plate a lawn on TSA plates. Plates were allowed to dry. Sodium 
Citrate buffer was adjusted to pH 3.7, 4.7, 5.7, or 6.7. 6mm paper disks were 
saturated with 10µL sodium citrate or 10X CFS. Sodium citrate and CFS 
saturated disks were placed adjacent to one another on dried UPEC plates. CFS 
and sodium citrate-only disks were applied as controls. To determine whether 
inhibition occurred below disks, I removed the disks using sterilized tweezers. I 
then used a sterile loop to scrap the agar where the disk sat previously. The 
sample was then struck onto a secondary fresh TSA plate and incubated 
aerobically overnight. If inhibition occurred, I would expect to see either a zone of 
inhibition surrounding CFS disks or a clearing below the disk and a lack of growth 
on secondary plates. 
Acidification by paper disks did not restore CFS activity on agar plates 
(Figure 14). Samples from each plate grew UPEC overnight, showing that 
inhibition did not occur beneath CFS- or sodium citrate-impregnated disks (data 
not shown). Lack of activity cannot be due to CFS concentration because I used 
10X CFS. CFS activity has been detected in liquid culture, but not plated 
cultures. This may suggest the active molecule(s) may be sensitive to oxidation, 
as liquid cultures do not have the same oxygen exposure as plated cultures do. 
I used an alternative approach to verify inactivity of CFS on agar plates. 
TSA was acidified using HCl to pH 3.6 prior to autoclaving and pouring plates. 
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TSA with 1.5% agar did not solidify under acidic conditions. Agar concentration 
was increased to 2.5% in an attempt to ensure solidification of TSA plates. TSA 
with 2.5% agar concentration did not did not solidify. Therefore, attempts to 
create acidic TSA plates were unsuccessful and at this time CFS activity has not 
been detected on plates.  
 
Figure 14. CFS Activity on Agar Plates Acidified by Sodium Citrate Paper 
Disks. Localized acidification does not promote in bactericidal activity against 
UPEC on agar plates. Sodium citrate (NaC) impregnated disks (left) and CFS 
impregnated disks (right). 
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Solvent Extraction 
 Once concentrated CFS was determined to exhibit full bactericidal activity 
against UPEC, fractionation techniques resulting in CFS dilution could be utilized. 
Liquid-Liquid Solvent Extraction was used to fractionate CFS and MRS. In short, 
organic solvents have properties that differentiate them from water and allow 
molecules present in a sample to move from an aqueous phase (water) to an 
organic phase (solvent). In general, only molecules sharing properties with the 
solvent will migrate to the organic phase. This method allows for both 
fractionation and characterization of molecules that migrate to the organic phase. 
 20X concentrated CFS was used in all extractions. Solvent was added to 
CFS and the mixture was vortexed. The samples were then centrifuged at 3,500 
rpm for 10 minutes to separate aqueous and organic layers. Layers were 
separated into Eppendorf tubes and placed in the SpeedVac overnight to 
evaporate water and solvent from samples. Samples were re-suspended in 1 mL 
H2O pH 3.7 and incubated with UPEC. 
 The bactericidal molecule(s) of CFS were soluble in polar solvents, but not 
in non-polar solvents. When using 1 Solvent:1 sample ratios, incomplete 
extraction by several solvents was evident by bactericidal activity in both 
aqueous and organic fractions (Figure 15a). Moreover, acetone and acetonitrile 
did not form an organic phase when added to MRS. Increased solvent volume 
(5:1) resulted in more complete extraction of bactericidal molecules in the organic 
phase (Figure 15b). 
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 To further purify the bactericidal molecule(s), sequential extraction was 
performed using 1-butanol followed by ethyl acetate. The solvents were chosen 
for the differences in their polarities and abilities to donate protons. Sequential 
extraction of CFS resulted in a 1-butanol organic ethyl acetate aqueous phase 
that lost activity. In contrast, the 1-butanol organic ethyl acetate organic phase 
retained full bactericidal activity against UPEC (Figure 16a).  
Protein concentrations were measured in MRS, 1X 24-hour CFS, 1X 48-
hour CFS, and 10X 48-hour CFS sequential extracts. The 1-butanol aqueous 
phases contained proteins from samples, while the 1-butanol organic and ethyl 
acetate extracts did not contain proteins (Figure 16b). The bactericidal 
molecule(s) of interest appears to be (di)polar, non-proteinaceous, and organic in 
nature. 
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A = Aqueous phase  O = Organic phase 
1-B = 1-Butanol, Chl = Chloroform, EA = Ethyl Acetate, PE = Petroleum 
Ether, Benz = Benzene, Ace = Acetone, Aceto = Acetonitrile 
 
Figure 15. Molecules contributing to CFS bactericidal activity are soluble in 
select organic solvents. Solvents were added to 20X CFS. Aqueous and 
organic layers were separated after extraction and solvents evaporated by 
SpeedVac. Fractions were then re-suspended in H2O pH 3.7 and incubated with 
UPEC. Molecules with bactericidal activity were soluble in 1-butanol, ethyl 
acetate, acetone, and acetonitrile. Acetone and acetonitrile were miscible in 
water and did not form organic layers when added to MRS. a) 1 CFS:1 solvent 
incomplete extraction occurred. b) With increased solvent volume (1 CFS:5 
solvent), more complete extracts were obtained, as evidenced by inactive 
aqueous phases. 
a)	
b)	
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Figure 16. Sequential Extraction of CFS in 1-Butanol and Ethyl Acetate 
removes proteins and tri-peptides from CFS. Sequential extraction of 20X 
CFS was performed using 1-butanol and ethyl acetate. 1-BA = 1-Butanol 
Aqueous phase, 1-BO = 1-Butanol Organic phase, EAA = Ethyl Acetate Aqueous 
phase, EAO = Ethyl Acetate Organic phase. a) Sequentially extracted fractions 
retain bactericidal activity against UPEC. b) Sequential extraction removes 
proteins and tri-peptides from MRS and CFS. Protein concentrations were 
determined by BCA colormetric assay. 
a)	
b)	
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CHAPTER V 
CHARACTERIZING AND DETERMINING CFS MECHANISM OF 
BACTERICIDAL ACTIVITY AGAINST UPEC 
Introduction & Rationale 
 CFS of Lactobacilli has been shown to have broad spectrum activity 
against a wide array of pathogens2-4,11-12,34,44-45,47,67-69. Due to this broad 
spectrum of activity, Lactobacilli may produce a molecule(s) with 
decontamination or therapeutic properties.  If the molecule(s) has potential for 
use in ecological or medical fields, understanding the mechanism of action is 
necessary prior to application. 
Many pathogens have developed antibiotic resistance with associated 
increases in morbidity and mortality46. The increased rate of antibiotic resistance 
exceeds the development and identification of new antibiotic that may be 
effective against resistant strains. Consequently, only a limited cache of 
antibiotics exist to combat bacterial infections. Various bacterial species have 
been identified to production molecules with bactericidal activity that may have 
application as new antibiotic treatments. For instance, recently researchers have 
identified lugdunin, a bacteriocidal molecule produced by Staphylococcus 
lugdunensis with efficacy against the colonization of methicillin-resistant 
Staphylococcus aureus, Glycopeptide intermediate-resistant S. aureus, 
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vancomycin-resistant Enterococcus, and other infectious bacteria47. If 
Lactobacillus crispatus CFS contains a molecule that is effective at inhibiting a 
broad spectrum of pathogens, then the molecule may be effective against 
antibiotic resistant strains with downstream application as an antibiotic. 
Various Lactobacillus spp. have been investigated for their bactericidal 
activity. Inhibitory activity has been attributed to H2O2, organic acids, or 
bacteriocins2,4,11,35,44-45,68,70,82. As shown previously, these molecules do not or 
are unlikely to be responsible for the bactericidal activity of L. crispatus. The 
capability of Lactobacilli to produce multiple bacteriostatic or bactericidal 
molecules would suggest that the genus has multiple mechanisms of action 
against pathogens. One study has shown that when a spotted lawn assay is 
performed using L. crispatus cells on a UPEC lawn, UPEC does not grow within 
the circumference of the cell spot, but a zone of inhibition did not form around the 
cell spot. CFS spotted on the UPEC lawn did not inhibit UPEC growth9. This 
would suggest either cell contact-dependent inhibition, production of a non-
diffusible bactericidal molecule, or concentration-dependence of the bactericidal 
molecule. Here, we investigate the mechanism by which L. crispatus inhibits 
UPEC colony formation independent of cell contact. 
CFS of Lactobacillus spp. has been documented to have inhibitory activity 
when Lactobacilli are incubated in MRS for only 24 hours11. Inhibitory activity, 
however, was not completely bactericidal as evidenced by the presence of viable 
target pathogens. Other research has shown complete bactericidal effects of 
		
48	
CFS against target pathogens after incubating Lactobacillus in MRS for 48 
hours4,9-10,44,70. This information suggests two possibilities: 1) bactericidal 
molecules are concentration-dependent, or 2) bactericidal molecules are only 
produced during late-exponential growth or stationary phase. 
In previous studies, a mechanism of action has not been proposed or 
investigated. A first step to understand the mechanism of action would be to 
observe the morphology of CFS incubated cells. The morphology of cells can 
elucidate the type of damage occurring in cells and can assist in determining a 
mechanism of action.  
Kinetics and Susceptibility 
Kinetics 
 Lactobacillus spp. CFS has been shown to inhibit pathogens within 24 
hours of incubation2-4,9-11,35,44-45,67,82. However, the rate of killing has not been 
determined. This knowledge is necessary if the active molecule is to be used in 
ecological or medical fields for dosing purposes. Thus, UPEC was incubated in 
CFS and colony-forming units were quantified over time to determine the kinetics 
of bactericidal activity. Incubation of UPEC with CFS had a bactericidal effect that 
began within 4 hours and resulted in undetectable CFUs by 16 hours. The 
bactericidal effect was exponential over time with an initial decrease of 3.1 x 106 
cells between 0- and 4-hour time points. Cell death was rapid; by 4 hours of 
incubation in CFS, 70.00% of UPEC cells had died and by 6 hours 99.99% of 
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cells were dead. Additionally, in all experiments performed, no UPEC CFUs 
have been observed when incubated in CFS (Figure 17). 
 
Figure 17. CFS kills UPEC logarithmically over time. Uropathogenic E. coli 
(UPEC) was incubated with either L. crispatus cell free supernatant (black) or 
MRS medium (grey). a) UPEC incubated in CFS decreased in viability 
logarithmically over time. Loss of viable UPEC cells began within 4 hours and 
were undetectable by 16 hours of incubation. The limit 
 
CFS Activity based on L. crispatus Growth Phase and Incubation Time 
 It remains unclear if the bactericidal molecule(s) is constitutively produced, 
produced only during a specific stage of growth, or when it reaches inhibitory 
concentrations. It is also unknown if incubating L. crispatus longer results in 
increased bactericidal activity. If the active molecule(s) is constitutively produced 
but is concentration-dependent, then I would expect to see a gradual increase in 
CFS activity with increased incubation time. If the active molecule(s) is not 
produced constitutively, then I would expect to see a sudden increase in 
bactericidal activity. 
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 48-hour liquid cultures of L. crispatus were standardized to an OD600 of 
0.05 in 6 mL of fresh MRS. OD was measured every 6 hours to obtain a growth 
curve. CFS was obtained from cultures at each time point. UPEC was incubated 
in CFS from each time point and quantified after 24 hours of incubation to assess 
bactericidal activity. 
CFS did not have any bactericidal activity against UPEC until late 
exponential/early stationary phase (Figure 18). This rapid increase in bactericidal 
activity supports production of sufficient concentrations of bactericidal 
molecule(s) during late exponential growth of L. crispatus.  
I suspected the partial bactericidal activity observed against pathogens by 
previous research11 was due to Lactobacillus incubation time in MRS. To 
determine if bactericidal activity of Lactobacillus was due to incubation time or 
was growth phase-dependent, CFS was obtained from L. crispatus cultures 
every 24 hours and incubated with UPEC. 
To determine when CFS gains activity and during which growth phase L. 
crispatus either begins production of the active molecule(s) or when minimum 
inhibitory concentration is reached, a growth curve was performed and CFS 
obtained at each time point. UPEC was incubated with CFS obtained at each 
time point and CFUs quantified. 
Because 48-hour CFS has complete bactericidal activity against UPEC, it 
was suspected that 24-hour CFS would show partial, but not complete activity as 
seen by previous researchers11. Contrary to previous findings, 24-hour CFS did 
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not exhibit any bactericidal activity against UPEC. However, 48-, 72-, and 96-
hour CFS showed complete bactericidal activity against UPEC (Figure 19). 
Longer incubation time did not exhibit an increased rate of bactericidal activity 
within 4 hours of incubation. I conclude that CFS only becomes bactericidally 
active when L. crispatus reaches early stationary phase and that longer L. 
crispatus incubation time does not result in increased activity against UPEC. 
 
Figure 18. Bactericidal activity of CFS against Lc40 growth. Growth curve of 
L. crispatus clinical isolate Lc40. Bactericidal activity of Lc40 CFS obtained at 
each measured growth curve time point. Lc40 CFS has a rapid increase in 
bactericidal activity against UPEC between 36 and 42 hours suggesting 
bactericidal molecule production occurs in late exponential/early stationary 
phase. 
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Figure 19. Effect of Lactobacillus incubation time on bactericidal activity. L. 
crispatus was incubated in MRS up to 96 hours. CFS was obtained from the 
culture every 24 hours and incubated with UPEC. MRS and 24-hour CFS 
exhibited no bactericidal activity against UPEC. 48-, 72-, and 96-hour CFS 
exhibited similar killing activity to one another and resulted in full bactericidal 
activity against UPEC. 
 
UPEC Susceptibility 
 In previous experiments, UPEC cultures had been standardized to an 
OD600 of 1.0, which represents stationary growth phase. CFS had not been 
tested against UPEC in exponential growth phase and therefore it remained 
unclear if UPEC only experienced susceptibility to CFS during stationary phase 
or if CFS was effective against UPEC independent of growth phase. 
 I inoculated TSB with an overnight UPEC (standardized to OD600 of 0.05) 
culture and grew the culture aerobically until it reached an OD600 of 0.4, which is 
representative of mid-exponential growth phase. UPEC and CFS were mixed in a 
1:1 ratio as previously mentioned and CFUs were quantified at 0- and 24-hour 
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time points. UPEC was susceptible to the active molecule(s) in CFS 
regardless of growth phase (Figure 20). 
 
Figure 20. Susceptibility to CFS based on UPEC growth phase. CFS 
completely inhibits UPEC independent of UPEC growth phase. 
 
Susceptibility of Select Gram-negative and Gram-positive Clinical  
    
   Isolates 
 
 Escherichia coli, Staphylococcus aureus, and Enterococcus faecalis are 
known or suspected pathogens. S. aureus and E. faecalis are recognized for 
their resistance to antibiotic treatment87. Research has shown that antibiotic-
resistant strains of S. aureus are susceptible to CFS treatment10. E. faecalis 
susceptibility has not been investigated. 
Three E. coli strains were tested: CFT073 and NU14, both implicated in 
pyelonephritis, and a clinical isolate (Ec901). Clinical isolates of S. aureus 
(Sa910) and E. faecalis (Ef891) also were tested. The clinical isolates were 
obtained from urine samples obtained during previous Wolfe laboratory studies5-
		
54	
8,88. Cultures were standardized to an OD600 of 1.0. Samples were incubated 
in CFS as previously mentioned.  
Bacteria incubated in MRS did not exhibit any change in CFU after 24 
hours. In contrast, E. coli and S. aureus samples incubated in CFS showed 
complete loss of CFUs by 24 hours. E. faecalis appeared largely resistant to CFS 
with only a slight, but significant, loss of CFUs by 24 hours of incubation (Figure 
21).  
CFS susceptibility testing was further expanded in an attempt to 
differentiate between commensal and pathogenic bacteria including UPEC with 
plasmid mediated resistance to β-lactam antibiotics. Commensal bacteria tested 
were L. gasseri, L. jensenii, and S. epidermidis. Pathogens tested were E. coli, K. 
pneumoniae, P. mirabilis, P. aeruginosa, B. cereus, E. faecalis, and S. aureus. 
Two of the E. coli isolates tested were transfected with a plasmid containing 
blaNDM-1 which encodes for the New Delhi metallo-beta-lactamase 1 (NDM-1).  
NDM-1 is an enzyme that confers resistance to β-lactam antibiotics. Β-
lactam antibiotics include penicillins, penams, cephalosporins, monobactams, 
and carbapenams. This family of antibiotics has broad-spectrum activity against 
both Gram-negative and Gram-positive bacteria. Β-lactams are generally used as 
an initial antibiotic to treat bacterial infections. 
CFS had bactericidal activity against all tested species with the exception 
of B. cereus (TABLE 4). CFS only had partial bactericidal activity against P. 
aeruginosa, E. faecalis, and S. epidermidis. CFS had full bactericidal activity 
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against the remaining tested bacteria: E. coli (CFT073, NU14, and NDM+ 
clinical isolates Acl25 and F35231-1), K. pneumoniae, P. mirabilis, L. gasseri, L. 
jensenii, and S. aureus.  
Therefore, CFS appears to inhibit certain isolates of both Gram-negative 
and Gram-positive bacteria. There was not a correlation between susceptibility to 
CFS and whether a bacterium is deemed commensal or pathogenic. Additionally, 
CFS had full bactericidal activity against multidrug-resistant bacteria (MDR). Due 
to this potential broad-spectrum activity, the active molecule(s) is not likely to be 
a bacteriocin, which tend to be active against only closely related organisms. 
Results instead suggest that the active molecule(s) in CFS is most likely to be an 
antibacterial AMP. 
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Figure 21. CFS activity against select Gram-negative and Gram-positive 
clinical isolates. Samples were incubated in CFS for 24 hours. E. coli and S. 
aureus (Sa910) were susceptible to CFS but E. faecalis (Ef891) showed 
substantial resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRS	 CFS	
*	 *	 *	 *	
*	
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Bacterium Commensal or Pathogen 
Gram-negative, 
Gram-positive Susceptibility 
Escherichia coli Pathogen Negative ++ 
   Acl25 Pathogen – NDM+ Negative ++ 
   F35231-1 Pathogen – NDM+ Negative ++ 
Klebsiella pneumoniae Pathogen Negative ++ 
Proteus mirabilis Pathogen Negative ++ 
Pseudomonas 
aeruginosa 
Pathogen Negative + 
Bacillus cereus Pathogen Positive - 
Enterococcus faecalis Pathogen Positive + 
Lactobacillus gasseri Commensal Positive ++ 
Lactobacillus jensenii Commensal Positive ++ 
Staphylococcus 
aureus 
Pathogen Positive ++ 
Staphylococcus 
epidermidis 
Commensal Positive + 
Table 4. Susceptibility of select Gram-positive and Gram-negative 
organisms to CFS. Organisms were incubated in CFS or MRS for 24-48 hours 
depending on the isolate’s recommended incubation time. Most organisms were 
susceptible to the bactericidal activity of CFS with the exception of B. cereus.  
++ = complete bactericidal activity, + = partial bactericidal activity, - = no 
bactericidal activity. 
 
CFS of Other Lactobacilli 
  A L. crispatus isolate with low bactericidal activity against UPEC had 
previously been identified10. However, I was unable to culture this isolate and 
replicate these results. If another isolate with low bactericidal activity could be 
identified, then its genome could be sequenced and compared to an isolate with 
high bactericidal activity. Variation in the genomes could identify genes of interest 
that may be responsible for production of the bactericidal molecule(s). 
CFS was obtained for three L. crispatus and one L. jensenii clinical 
isolates. UPEC was incubated in CFS for 24 hours and CFUs quantified. CFS 
from all Lactobacilli showed complete bactericidal activity against UPEC (Figure 
22).  
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Figure 22. CFS Activity of different Lactobacilli. UPEC was incubated in CFS 
from L. crispatus (Lc) or L. jensenii (Lj) for 24 hours and CFUs quantified. CFS of 
each Lactobacillus isolate tested showed complete inhibition of UPEC. 
 
Imaging 
As mentioned earlier, an initial step toward understanding the mechanism 
of inhibition against UPEC should be observation of cell morphology. CFS may 
cause damage to cells that is evident in bright field, immunofluorescent, and/or 
transmission electron microscopy. Each of these techniques can elucidate the 
type of damage occurring to cells that results in loss of viability within 24 hours.  
Bright field microscopy will allow for basic analysis of cell morphology by 
observation of overall cell structure and cytoplasmic content. For example, 
damaged cells may show atypical morphology or blebbing. Immunofluorscent 
microscopy allows for targeted imaging of specific cellular components such as 
membranes and nucleic acids. Transmission electron microscopy (TEM) allows 
for detailed observation of cell membranes and organization of intracellular 
components. 
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Phase Contrast Microscopy 
UPEC incubated in CFS or MRS for 24 hours were observed at 1000X 
under phase contrast microscopy. Treated cells appearred smaller and more 
round compared to controls incubated in MRS medium (Figure 23). Zooming in 
on images revealed decreased cytoplasmic density in CFS-incubated cells when 
compared to MRS-incubated cells. 
 
Figure 23. Phase contrast microscopy of UPEC incubated in CFS or MRS 
(1000X). UPEC incubated in CFS (right) or MRS (left) for 24 hours were 
observed at 1000X under phase contrast microscopy. CFS-incubated cells have 
atypical morphology and decreased intracellular density. 
 
Immunofluorescent Microscopy 
Live/Dead Staining UPEC cells incubated in CFS or MRS were stained 
using the BacLight Bacterial Viability Kit™. The kit uses two nucleic acid dyes, 
Syto9 and propidium iodide. Syto9 is a green fluorescent dye that readily enters 
all cells. Propidium iodide is a larger red dye that can only enter cells with a 
compromised membrane.  
CFT073	 t	24	hours	
MRS	 SCS	
CFT073	at	24	hours	
MRS	 SCS	
CFT073	at	24	hours	
MRS	 SCS	
FS	
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 After 24 hours of incubation, cells were stained following the supplier’s 
protocol. MRS incubated cells appeared green, suggesting intact membranes 
(Figure 24). Approximately 70% of cells incubated in CFS stained red with 
propidium iodide, suggesting compromised membranes. 
Membrane and Nucleic Acid Staining UPEC cells incubated in CFS or 
MRS were stained using FM 4-64 membrane and Hoescht 33342 nucleic acid 
fluorophores to observe changes in morphology and membrane permeability 
over time. FM 4-64 (red) stains plasma membranes and the fluorophore is 
internalized rapidly over time80. Hoescht 33342 (blue) binds the minor groove of 
DNA preferentially at A-T rich double-stranded regions81. I experimentally 
determined that the Hoescht fluorophore only entered UPEC cells with 
compromised membranes. CFS- and MRS-incubated UPEC were stained at 0-, 
6-, 12-, and 18-hours after incubation.  
After 6 hours of incubation, CFS-incubated cells appeared smaller than 
MRS-incubated cells (Figure 25), consistent with phase contrast images. MRS-
incubated cells localized FM 4-64 within the membrane, while CFS-incubated 
cells showed diffusion of FM 4-64 into the cytoplasm, suggesting increased rate 
of internalization potentially due to compromised membrane integrity. Decreased 
fluorescence intensity of CFS-incubated cell membranes, compared to MRS-
incubated cells, supports a loss of membrane integrity. The Hoescht fluorophore 
was able to penetrate CFS-incubated UPEC membranes by 12 hours and was 
strongly fluorescent at 18 hours, suggesting increased DNA binding. Hoescht did 
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not enter MRS-incubated cells at any time point. As with Live/Dead staining, 
these results suggest CFS-incubated cells have compromised membranes. 
Hoescht fluorescence in CFS-incubated cells suggests the minor groove of DNA 
and A-T rich double-stranded regions maintain their structural integrity at 12 and 
18 hours after incubation. Compromised membrane integrity at 12- and 18-hour 
time points correlates with loss of CFU in Figure 17. 
I attempted to perform the previous procedure to compare UPEC against 
a Gram-positive bacterium. This could not be achieved, as the Hoescht 
fluorophore entered untreated Gram-positive cells (Figure 26). This suggests 
exclusion of Hoescht in UPEC cells is due to the presence of an outer membrane 
that is initially impenetrable to the Hoescht fluorophore. Because Hoescht enters 
untreated S. aureus cells, a Live/Dead Stain also would not be a viable option 
either as Hoescht and propidium iodide are similar in size and these cells would 
fluoresce red, suggesting they are dead when that would not be the case. 
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Figure 24. Live/Dead Stain of UPEC incubated in MRS or CFS. UPEC cells 
incubated in CFS or MRS were stained after 24 hours. CFS-incubated cells have 
compromised membranes as evidenced by entry of propidium iodide into cells 
(red). 
 
 
 
MRS	 CFS	
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Figure 25. Membrane and Nucleic Acid Staining of CFS- and MRS-
incubated UPEC. UPEC was stained with FM 4-64 membrane fluorophore (red) 
and Hoescht 33342 nucleic acid fluorophore (blue). CFS-incubated cells showed 
altered morphology by 6 hours of incubation and compromised membranes by 12 
hours of incubation.  
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Figure 26. Membrane and Nucleic Acid Staining of E. coli versus S. aureus. 
Hoescht fluorophores readily enter Gram-positive S. aureus but not Gram-
negative E. coli prior to incubation in CFS.  
 
Transmission Electron Microscopy 
 Transmission Electron Micrographs (TEM) were obtained of UPEC cells 
incubated with CFS or MRS. MRS-incubated cells appeared ellipsoid with diffuse 
cytoplasm (Figure 27a). CFS-incubated cells were smaller with irregular 
morphology compared to MRS-incubated cells. The cytoplasm of CFS cells 
appeared granular and less dense than MRS-incubated cells. Increased 
magnification showed that CFS-incubated cells have undergone plasmolysis with 
compromised cytoplasm and plasma membranes (Figure 27b/c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.	coli	 S.	aureus	
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Figure 27. Incubation of UPEC in CFS compromises the integrity of cell 
cytoplasm and membranes. TEM of MRS-incubated UPEC (left) versus CFS 
incubated UPEC (right) shows plasmolysis with compromised integrity of 
cytoplasm and periplasm in CFS-incubated cells. a) 3000X, b) 8000X, c) 13000X 
magnifications. 
a)	
b)	
c)	
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CHAPTER VI 
DISCUSSION AND CONCLUSION 
 I propose that Lactobacillus crispatus produces a potentially novel dipolar, 
organic molecule with broad-spectrum activity that is concentration-dependent 
and salt-sensitive. This currently unidentified molecule(s) effectively and 
reproducibly inhibits colony formation of UPEC, apparently by a mechanism that 
causes plasmolysis. Identification of this molecule(s) is of high importance as it 
may contribute to human health either as a decontaminant or as a therapeutic in 
an era when antibiotic resistance is increasing. 
 I have shown that a urinary isolate of L. crispatus (Lc40) produces 
concentrations of H2O2 and organic acids significantly lower than those required 
to inhibit pathogen growth or survival (Table 2). MRS medium conditioned with 
physiologically produced concentrations of H2O2 and/or organic acids did not 
result in decreased UPEC viability when compared to unconditioned MRS 
medium (Figure 3). Surprisingly, previous researchers have not performed this 
simple experiment, i.e., to measure physiologically produced concentrations of 
H2O2 and organic acids and to determine their contributions to CFS bactericidal 
activity. Previous researchers have either measured concentrations of these 
molecules and not tested the physiologically produced concentrations or tested 
ranges of concentrations to determine at which concentration inhibition would 
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occur. Furthermore, the bactericidal activity of CFS was stable even upon 
boiling and over a range of storage times (Figures 4 & 5). Since H2O2 and 
organic acids degrade with heat and with time, these observations support my 
contention that H2O2 and organic acids cannot be responsible for the observed 
bactericidal activity against UPEC. In light of my results, it seems counterintuitive 
to attribute bactericidal activity of CFS to H2O2 or organic acids using the 
methods of previous researchers and therefore I suggest previous research be 
re-analyzed and re-interpreted. 
Because the bactericidal activity of CFS was extremely stable, I also 
conclude that the bactericidal molecule(s) is not likely to be proteinaceous in 
nature. Proteins tend to denature with exposure to extreme temperatures and 
temperature-conditioned CFS stored up to two weeks did not exhibit a decrease 
in activity compared to unconditioned CFS (Figure 4). Moreover, 1-butanol 
organic extraction removed the majority of proteins and peptides from CFS, yet 
bactericidal activity was retained (Figure 16). I conclude that the active 
molecule(s) is likely not proteinaceous. Together, these results suggest the 
bactericidal activity of L. crispatus CFS is not due to H2O2, organic acids, 
proteins, peptides, or bacteriocins; which have been previously credited for 
pathogen inhibition. 
Bacteriocins have many classes defined by various criteria. Based solely 
on the definition of a bacteriocin it appears unlikely that the active molecule(s) in 
CFS is a bacteriocin. The molecule(s) has broad-spectrum activity against 
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distantly related genera such as Escherichia, Klebsiella, Proteus, and 
Pseudomonas (Table 4). Based on this definition alone the only Classes of 
bacteriocin the active molecule(s) could fall into are Subclass IIa or Class IV. 
Subclass IIa is supported by the heat stability of the molecule(s) when full activity 
is retained after heating CFS for one hour at 100°C (Figure 4). However, as 
previously stated, the active molecule(s) acts against distantly related organisms 
and is unlikely to be a traditionally characterized bacteriocin. Classes I and III are 
composed of amphipathic molecules and should therefore be soluble in both 
polar and non-polar solvents. This is not the case. The active molecule(s) was 
only soluble is polar solvents suggesting the bactericidal molecule(s) is polar in 
nature (Figures 15 & 16). Additionally, Class III bacteriocins result in cell lysis. 
CFS’ mechanism of action against UPEC is shown to result in cellular 
plasmolysis (Figure 27). Class IV bacteriocins have more variability in their 
characterisitics and the molecule(s) may fit into this class. However, as stated the 
molecule(s) act against distantly related genera and is most likely not a 
bacteriocin. AMPs are more loosely defined and characterized based solely on 
target organism. Therefore, I would suggest that the bactericidal molecule(s) in 
CFS is an antibacterial AMP. 
The bactericidal activity of CFS was sensitive to dilution and salt 
concentration (Figures 10-12). Samples diluted in PBS, which has increased salt 
concentration compared to H2O, retained activity at lower CFS concentrations 
(Figure 12). Retention of activity in saline conditions is relevant to use of the 
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active molecule(s) as a therapeutic agent. The human body has greater 
salinity than H2O, making this result physiologically relevant; however, actual 
salinity varies based on anatomical tissue type and location. Once the identity of 
the active molecule(s) is determined, then its concentration in 1X CFS should be 
measured. Based on dilution experiments, an approximate minimum inhibitory 
concentration could be approximated and tested. 
The pH of urine from healthy individuals ranges from 5.0-7.0. At this pH, 
the bactericidal molecule(s) would be inactive. Lactobacillus spp. have been 
shown to reduce the pH of the medium they are grown in. I would speculate that 
in the bladder the genus would also reduce the pH of the environment. The 
volume and surface area of the bladder are significantly larger than that of a test 
tube. Therefore, I suggest that, rather than acidifying the entire bladder, L. 
crispatus reduces the pH of its microenvironment. The localized acidification of 
the microenvironment would allow for the bactericidal activity of secreted 
antimicrobial molecule(s). 
Incubating L. crispatus for 48 hours was required for maximum 
bactericidal activity, as bactericidal activity did not occur until 42 hours of L. 
crispatus growth; however, the effect was incomplete at this stage of growth 
(Figure 18). Yet, incubating L. crispatus longer than 48 hours did not alter the 
kinetics of bactericidal activity (Figure 19). This suggests the active molecule(s) 
is only produced or reaches effective concentrations during late exponential 
growth or in early stationary phase. Production or effective concentrations result 
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only after L. crispatus reaches late exponential growth. Holding L. crispatus in 
stationary phase beyond 48 hours did not result in increased bactericidal activity 
against UPEC, further supporting production or effective concentration during 
late exponential growth. To determine whether the molecule(s) is produced 
constitutively 24-hour CFS could be concentrated and tested against UPEC to 
evaluate bactericidal activity. If concentrated 24-hour CFS has bactericidal 
activity then it would be hypothesized that L. crispatus constitutively produces 
and secretes bactericidal molecule(s) rather than only producing the bactericidal 
molecule(s) at late exponential growth phase. An alternative is a possible 
saturation effect, where concentration beyond an undetermined threshold does 
not exhibit increased efficacy or production of a very stable molecule(s) only 
during late exponential growth and production does not continue through 
stationary phase. Another variable may be the pH of L. crispatus growth medium 
over incubation time. L. crispatus reduces the pH of MRS by 48 hours of 
incubation. To determine if lack of bactericidal activity prior to 42 hours of 
incubation is a pH effect, the pH of the growth medium would need to be 
measured over time and bactericidal activity of CFS determined at each time 
point. However, determination of when the cells produce the molecule(s) and 
concentrations produced over L. crispatus growth must wait until the molecule(s) 
is identified. 
 The active molecule(s) of CFS was soluble in polar/dipolar solvents, 
including 1-butanol, acetone, acetonitrile, and ethyl acetate (Figure 15). This 
		
71	
suggests that the active molecule(s) is polar in nature. 1-butanol, acetone, and 
ethyl acetate contain oxygen atoms that are not involved in linkage within their 
primary structure (Figure 6). Acetonitrile contains a terminal triple bonded 
nitrogen atom. Acetone, acetonitrile and ethyl acetate are unsaturated (i.e., 
having double or triple bonded atoms).  These properties suggest the active 
molecule(s) in CFS may form hydrogen or polar covalent bonds with the 
electronegative atoms of solvents, facilitating migration into the organic phase. 
The molecule(s) was soluble in alcohol (1-butanol), ester (ethyl acetate), and 
ketone (acetone) solvents, but not in hydrocarbon or chlorinated solvents (Table 
3). This diverse solubility does not assist in classification of the molecule(s). 
However, based on the solubility profile of the bactericidal CFS molecule(s), I 
conclude the molecule(s) is a (di)polar organic molecule.  
  Attempts to fractionate CFS by size were unsuccessful (Figures 7-9). 
FPLC failure was likely the result of high dilution factors that occur during the 
liquid chromatography process. Size exclusion spin columns did not result in 
dilution of CFS, but still resulted in fractions without bactericidal activity. It is 
possible the active molecule(s) may be bound to spin column membranes, even 
though low-binding membranes were used. These results may also suggest CFS 
bactericidal activity requires more than one molecule. During size exclusion, 
molecules may be separated and unable to form an active complex. 
Furthermore, bactericidal activity may be due to a complex composed of 
molecules of different sizes. An alternative is that one molecule requires a 
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cofactor for activity. When CFS was diluted, the cofactor may not have been 
present in high enough concentrations for activity. Because the active 
molecule(s) can be extracted and retains full bactericidal activity, if a cofactor is 
required it must possess similar properties to that of the active molecule(s), but 
may also be of a different molecular weight.  
 Attempts to show CFS activity on agar plates were unsuccessful (Figure 
14). Tryptic soy contains dibasic potassium phosphate buffer that maintains plate 
pH at approximately pH 7.3. pH measurements of TSA and CFS plated on TSA 
showed that acidic pH conditions are not retained after CFS dries on TSA. The 
increase in pH is most likely due to the buffer in TSA and explains why 
bactericidal activity has not been observed in plated conditions. Researchers 
have conducted experiments with TSA buffered between pH 3.9-8.0, showing 
TSA can be acidified. Plates acidified below 3.9 did not solidify even with 
increased agar concentration. Therefore, CFS activity on acidified plates could 
not be evaluated. Localized acidification by use of paper disks did not promote 
CFS activity. Dibasic potassium phosphate buffer present in TSA may neutralize 
the acidic paper disks and could explain the lack of CFS activity on agar plates. 
To further investigate bactericidal activity on agar plates, a different medium or 
modified TSA without dibasic potassium phosphate would need to be used. If a 
buffer were to be used in the medium then it would have to be a buffer that is 
capable of maintaining medium pH at 3.7. If activity is still not observed in plated 
conditions then the active molecule(s) in CFS may be sensitive to oxidation. CFS 
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is exposed to increased oxygen concentrations in plated conditions compared 
to liquid cultures, but further experiments must be performed to evaluate 
sensitivity to oxidation.  
 L. crispatus CFS showed efficacy against some species implicated in 
various diseases and recognized to exhibit troubling rates of antibiotic resistance 
(Figure 20, Table 4). CFS had full bactericidal activity against NDM+ UPEC with 
resistance to β-lactam antibiotics, which include carbapenems, cephalosporins, 
and penicillin derivatives (Table 4). Not only does this support broad-spectrum 
activity but also shows the potential application as a treatment for MDR bacterial 
infections. Carbapenems, cephalosporins, and penicillins are traditionally used 
as a first line therapeutic for bacterial infections. With increased resistance, a 
decrease in the rate of new antibiotic development, and a limited cache of 
antibiotics it is critical to identify and develop new therapeutics against the 
increasing prevalence of MDR bacterial infections. In a limited study, a low 
efficacy isolate of L. crispatus was not identified (Figure 22). The CFS of the 
Lactobacillus isolates tested all showed complete inhibition of UPEC. However, 
in this preliminary screen, H2O2, organic acids, proteins, and bacteriocins could 
not be excluded as contributing factors to the observed inhibition, as tests were 
not performed to evaluate the concentration of each molecule in their CFS. 
These data suggest the active molecule(s) produced by L. crispatus has broad-
spectrum activity and may be ubiquitous among other L. crispatus clinical 
isolates tested. 
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 Incubation of UPEC with CFS had a bactericidal effect that was 
exponential over time beginning within 4 hours and resulted in undetectable 
CFUs by 16 hours (Figure 17). Cell death was rapid; by 4 hours of incubation in 
CFS, 70% of UPEC cells had died and by 6 hours 99.99% of cells were dead. 
Additionally, in all experiments performed, no UPEC colony-forming units have 
been observed when incubated in CFS. This result suggests cells cannot 
develop resistance to the active molecule(s) in CFS under conditions used. It is 
possible that cells are exposed to extremely lethal concentrations of the active 
molecule(s) and are unable to develop resistance due to rapid cell death. 
Experiments would need to be conducted using sub-lethal concentrations, such 
as 60% CFS, and cells passaged through multiple generations to determine if 
resistance can be developed by UPEC. The bactericidal molecule(s) present in 
CFS has also been shown to be extremely stable retaining full bactericidal 
activity when stored for up to three months at room temperature (Figure 5). 
Stability is of critical importance when considering use of this molecule(s) as a 
therapeutic. That the CFS can be lyophilized or stored as a liquid up to three 
months and still retain full activity could lead to its application as a therapeutic in 
underdeveloped countries where the storage of a liquid or refrigerated 
therapeutic may not be feasible.  
Observation of CFS-treated UPEC by phase-contrast microscopy showed 
smaller cells with a rounded morphology compared to UPEC incubated in MRS 
(Figure 23). Cells also appeared to have decreased cytoplasmic density, 
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suggesting intracellular components may be degraded or leaking from cells. 
Live/Dead staining showed a majority of CFS-incubated cells had compromised 
membranes, allowing propidium iodide (PI) to enter cells and stain nucleic acids 
(Figure 24). This also showed that nucleic acids are retained within CFS-treated 
cells after a 24-hour incubation period. Immunofluorescent staining with FM 4-64 
membrane and Hoescht 33342 nucleic acid fluorophores showed an increased 
number of cells with FM 4-64 internalization at 6 hours in CFS-incubated cells, 
suggesting membranes are compromised by this time. Whether membrane 
damage is the cause of death or a secondary effect to cell death has not been 
determined at this time. Hoescht was seen to enter CFS-incubated cells by 12 
hours (Figure 25). CFS-incubated cells had increased fluorescence at 18 hours 
compared to MRS-incubated cells, which do not internalize Hoescht at any time 
point. I could not determine if Gram-positive species show the same permeability 
when incubated with CFS as Gram-negative E. coli, as S. aureus readily 
internalized both Hoescht and FM 4-64 prior to incubation with CFS (Figure 26). 
This result is consistent with results of Gram-positive bacterium research, where 
Hoescht is used in experiments as a nucleic acid fluorophore for live cells. To 
determine if Gram-positive species show similar damage to E. coli after 
incubation in CFS, we would need to obtain TEMs to observe detailed 
cytoplasmic and morphological differences compared to MRS-incubated cells. 
Alternatively, we could use a different fluorophore, one that permeates Gram-
negative and Gram-positive cells in a similar manner. PI intercalates between 
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intact double-stranded DNA. Hoescht binds the minor groove of DNA at A-T 
rich regions. The ability of PI and Hoescht to bind the DNA of CFS-incubated 
cells suggests DNA architecture was not affected by the active molecule(s) in 
CFS since DNA remained double-stranded and A-T rich minor groove regions 
were apparently intact. Closer analysis by TEM of UPEC incubated in CFS 
revealed atypical morphology compared to MRS-incubated cells (Figure 27). 
Cells showed signs of plasmolysis with compromised plasma membranes and 
granulated cytoplasmic contents. Granular cytoplasmic contents could explain 
the appearance of less dense cytoplasm observed by phase contrast imaging 
(Figure 23).  
 Much still needs to be learned about the bactericidal activity of L. crispatus 
CFS. Many characteristics of the bactericidal molecule(s) in CFS have been 
determined; however, the identity of the molecule(s) has still not been elucidated. 
Identification of the molecule(s) will assist in further determining characteristics of 
the molecule(s), potential L. crispatus genes responsible for production of the 
molecule(s), a mechanism of action, minimum inhibitory concentration, and 
potential applications.  
Characterization could include the classification and structure of the 
molecule(s). Determination of class and structure will provide information about 
how the molecule(s) acts against its target and in which anatomical or ecological 
niches, if any, it would be active. If the molecule(s) is only active in specific 
anatomical or ecological niches then modification of its structure could result in a 
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molecule(s) with more diverse activity in various niches. As the active 
molecule(s) is pH-sensitive, its structure could be modified to enable activity in a 
more pH neutral environment. 
Determination of the gene responsible for production of the molecule(s) is 
another important step toward use of the molecule(s) as a therapeutic. Once the 
gene is determined, it can then be introduced into a bacterium with a shorter 
generation time. Prior to introduction, however, the mechanism of action would 
need to be determined. Insertion of the gene into a susceptible bacterium would 
ultimately result in decreased production of the active molecule(s) compared to L. 
crispatus. By determining the mechanism of action we may be able to alter the 
genome of a bacterium deeming it resistant; and consequently, the ability to 
produce the active molecule(s) more rapidly than L. crispatus. If the molecule(s) 
can be used as a decontaminant or therapeutic then more rapid production (and 
potentially higher yield) could help to result in quicker distribution as well as 
minimize cost.  
Based on the results presented here, I suggest that L. crispatus produces 
an extremely stable, potentially novel dipolar, organic molecule with broad-
spectrum activity that is concentration-dependent, salt-sensitive and that results 
in plasmolytic action against its target. Identification of the molecule(s) could lead 
to its application as a decontaminant or therapeutic contributing to human health. 
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